Expanding medical indications for the CompuFlo Epidural Instrument and commencing disposable sales to a leading veterinary and academic institution

MILESTONE MEDICAL (USU6005B1045)

RB_ASO: Expanding medical indications for the CompuFlo Epidural Instrument and commencing disposable sales to a leading veterinary and academic institution
Data: 2022-05-27
Firma: MILESTONE MEDICAL INC

Spis tresci:

1. RAPORT BIEŻĄCY

2. MESSAGE (ENGLISH VERSION)

3. INFORMACJE O PODMIOCIE

4. PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ

Nazwa arkusza: RAPORT BIEŻĄCY

KOMISJA NADZORU FINANSOWEGO Raport bieżący nr 4 / 2022 Data sporządzenia: 2022-05-27 Skrócona nazwa emitenta MILESTONE MEDICAL Temat Expanding medical indications for the CompuFlo Epidural Instrument and commencing disposable sales to a leading veterinary and academic institution Podstawa prawna Art. 17 ust. 1 MAR - informacje poufne. Treść raportu: The Board of Directors of Milestone Medical Inc. _WAR: MMD, "the Company", "the Issuer"_, today announced that it has commenced sales of its CompuFlo Epidural instrument disposables at a leading veterinary and academic institution following a successful research study and evaluation. The veterinary institution has initially begun using the CompuFlo Epidural instrument for maxillary nerve block procedures in horses with plans to expand into epidural procedures. The CompuFlo Epidural instrument can provide fellow veterinarians and students greater accuracy through real-time verification of needle location when performing a maxillary nerve block. The name of the veterinary institution cannot be disclosed for confidentiality reasons. The Board of Directors of the Company is pleased to announce the adoption of CompuFlo Epidural instrument by this leading veterinary and academic institution. The Company is continually evaluating additional channels to commercialize its technology, including new medical indications. Veterinary medicine is just one example of another market that may benefit from CompluFlo Epidural instrument. The Board of Directors of the Company believes that the extensive prior studies, spanning epidural, peripheral nerve block, intra-articular, and veterinary use cases reinforce the enhanced safety, improved outcomes, economic benefits and broad market potential of the instrument.

Nazwa arkusza: MESSAGE (ENGLISH VERSION)

MESSAGE _ENGLISH VERSION_

Nazwa arkusza: INFORMACJE O PODMIOCIE

MILESTONE MEDICAL INC _pełna nazwa emitenta_ MILESTONE MEDICAL _skrócona nazwa emitenta_ _sektor wg. klasyfikacji GPW w W-wie_ NJ 07039 . _kod pocztowy_ _miejscowość_ South Orange Avenue Livingston 220 _ulica_ _numer_ +11 973 535 2717 +11 973 535 2829 _telefon_ _fax_ _e-mail_ _www_ 27-5484393 _NIP_ _REGON_

Nazwa arkusza: PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ

PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ Data Imię i Nazwisko Stanowisko/Funkcja Podpis 2022-05-27 Keisha Harcum Controller Keisha Harcum

Identyfikator raportu	g3rnkvrut1
Nazwa raportu	RB_ASO
Symbol raportu	RB_ASO
Nazwa emitenta	MILESTONE MEDICAL INC
Symbol Emitenta	MILESTONE MEDICAL
Tytul	Expanding medical indications for the CompuFlo Epidural Instrument and commencing disposable sales to a leading veterinary and academic institution
Sektor
Kod	NJ 07039
Miasto	.
Ulica	South Orange Avenue Livingston
Nr	220
Tel.	+11 973 535 2717
Fax	+11 973 535 2829
e-mail
NIP	27-5484393
REGON
Data sporzadzenia	2022-05-27
Rok biezacy	2022
Numer	4
adres www

Serwis Ekonomiczny Polskiej Agencji Prasowej SA

2022 Copyright PAP SA - Wszelkie prawa zastrzezone.